Cross-sex Hormone Therapy
– Requires prior-authorization (6 month intervals)
Before
initiation of cross-sex hormone therapy, the following gender identity related
diagnoses need to be confirmed by a psychiatrist:
F64.0 (Transsexualism),
F64.2 (Gender identity disorder of
childhood), F64.8 (Other gender
identity disorders), and F64.9
(Gender Identity disorder, unspecified). The only gender identity disorder
diagnosis not requiring confirmation by a psychiatrist is
Z87.890 (Personal history of sex reassignment).
In some instances cross-sex hormone therapy has already been initiated
without a confirmed diagnosis of GD—either by a previous prescribing
physician or by the patient obtaining hormones
illicitly via the internet or other sources.
It is the responsibility of the prescribing physician (whether initiating
or continuing previously initiated therapy) to ensure there is a confirmed
diagnosis of GD. A psychosocial
assessment should be conducted and informed consent needs to be obtained by the
prescribing physician.
The
criteria for cross sex hormone therapy are as follows:
-
Persistent (> 1 year), well-documented gender dysphoria (with
confirmation of diagnosis by a psychiatrist),
-
Capacity to make a fully informed decision and to consent for
treatment;
-
Member must be at least 18 years of age;
-
If
significant medical or mental health concerns are present, they must be
reasonably well controlled.
The presence
of co-existing mental health diagnoses or medical comorbidities does not
necessarily preclude access to cross-sex hormones. However, these concerns
should be managed and stabilized prior to treatment of gender dysphoria.
Cross-sex hormonal interventions are not without risk for
complications, including (in some instances) irreversible physical changes.
Medical records should indicate that an extensive evaluation was completed to
explore psychological, family, and social issues both before and after
treatment. Prescribing providers should also document that all information has
been provided and understood regarding all aspects associated with the use of
cross-sex hormone therapy, including both benefits and risks.
In order to minimize risks of cross-sex hormone therapy, blood tests
should be used to monitor hormone levels.
Continued
authorization (beyond 6 months) of cross-sex hormone therapy is contingent on
providing the results of blood test hormone levels.
It is the responsibility of prescribers to avoid supraphysiologic hormone
levels (for the desired gender) and to not rely exclusively on patient requests
to determine hormone dosing. Hormone
doses should be reduced if supraphysiologic levels (for the desired gender) are
detected. Not staying within the
physiologic range (for the desired gender) increases the risk of harm to the
patient and liability for the prescribing physician.
Gender
Reassignment Surgery
– Requires prior-authorization
Readiness criteria for gender reassignment surgery include the
individual demonstrating progress in consolidating gender identity, and
demonstrating progress in dealing with work, family, and interpersonal issues
resulting in an improved state of mental health. In order to check the
eligibility and readiness criteria for gender reassignment surgery, it is
important for the individual to discuss the matter with a professional provider
who is well-versed in the relevant medical and psychological aspects of GD. The
mental health and medical professional providers responsible for the
individual`s treatment should work together in making a decision about the use
of cross-sex hormones during the months before the gender reassignment surgery.
Transsexual individuals should regularly participate in psychotherapy in order
to have smooth transitions and adjustments to the new social and physical
outcomes.
Services that
are considered cosmetic for men or women without gender dysphoria (who are
unsatisfied with their naturally endowed secondary sexual characteristics) are
also considered cosmetic for the treatment of gender dysphoria and are therefore
not covered. This is not an all-inclusive list:
·
Blepharoplasty – Removal
of redundant skin of upper and/or lower eyelids and protruding periorbital fat
·
Chin augmentation –
Reshaping or enhancing the size of the chin
·
Collagen injections
·
Cricothyroid
approximation – Voice modification that raises the vocal pitch by simulating
contractions of the cricothyroid muscle with sutures
·
Facial feminizing (e.g.,
facial bone reduction)
·
Hair removal / hair
transplantation
·
Laryngoplasty – Reshaping
of laryngeal framework (voice modification surgery)
·
Lip Reduction /
Enhancement – Decreasing / enlarging lip size
·
Liposuction –
Removal of fat
·
Mammaplasty –
Breast augmentation
·
Mastopexy – Breast lift
·
Rhinoplasty – Reshaping
of nose
·
Rhytidectomy – Face lift
·
Trachea shave/reduction
thyroid chondroplasty – Reduction of the thyroid cartilage
Cosmetic surgery includes any surgical procedure directed at
improving appearance, except when required for the prompt (i.e., as soon as
medically feasible) repair of accidental injury or for the improvement of the
functioning of a malformed body member.
Gender reassignment surgery must be preauthorized and
determinations are made on a case by case basis. Surgical treatment for
transsexualism (F64.0) may be
eligible for reimbursement when medical necessity and documentation requirements
outlined within this policy are met.
Surgical
treatment for gender dysphoria may be considered medically necessary when ALL
of the following criteria are met:
·
The individual is at least 18 years of age.
·
A gender reassignment treatment plan is created specific to an
individual beneficiary
·
The individual has a documented Diagnostic and Statistical Manual
of Mental Disorders -Fifth Edition, DSM-5 ™ diagnosis of GD—confirmed by a
psychiatrist:
A.
A marked incongruence between one’s experienced/expressed gender and
assigned gender, of at least 6 months duration, as manifested by at least two of
the following:
1.
A marked
incongruence between one’s experienced/expressed gender and primary and/or
secondary sex characteristics.
2.
A strong
desire to be rid of one’s primary and/or secondary sex characteristics because
of a marked incongruence with one’s experienced/expressed gender.
3.
A strong
desire for the primary and/or secondary sex characteristics of the other gender.
4.
A strong
desire to be of the other gender (or some alternative gender different from
one’s assigned gender).
5.
A strong
desire to be treated as the other gender (or some alternative gender different
from one’s assigned gender). A strong conviction that one has the typical
feelings and reactions of the other gender (or some alternative gender different
from one’s assigned gender).
B.
The condition is associated with clinically significant distress or impairment
in social, occupational, or other important areas of functioning.
1.
One letter from a mental health professional that has had, at
minimum, twelve months of psychotherapy therapy sessions attesting to all of the
following clinical criteria:
(i)
That any
co-morbid psychiatric or other medical conditions are stable and that the
individual is prepared to undergo surgery.
(ii)
That the
patient has had persistent and chronic gender dysphoria.
(iii)
That the
patient has completed twelve months of continuous, full-time, real-life
experience (i.e., the act of fully adopting a new or evolving gender role or
gender presentation in everyday life) in the desired gender.
(iv)
The
individual, if required by the mental health professional provider, has
regularly participated in psychotherapy throughout the real-life experience at a
frequency determined jointly by the individual and the mental health
professional provider.
(v)
Unless
medically contraindicated (or the individual is otherwise unable to take
cross-sex
hormones), there is documentation that the individual has participated in twelve
consecutive months of cross-sex hormone therapy of the desired gender
continuously and responsibly (e.g., screenings and follow-ups with the
professional provider).
(vi)
The
individual has knowledge of all practical aspects (e.g., required lengths of
hospitalizations, likely complications, and post-surgical rehabilitation) of the
gender reassignment surgery.
Codes
Used In This BI:
19301
Mastectomy, partial;
19303
Mastectomy, simple, complete
19304
Mastectomy, subcutaneous Deleted code eff 01/01/2020
53410
Urethroplasty, 1-stage reconstruction of male anterior urethra
53430
Urethroplasty, reconstruction of female urethra
54125
Amputation of penis, complete
54520
Orchiectomy, simple, w/or w/out testicular prosthesis, scrotal or
inguinal
approach
54660
Insertion of testicular prosthesis
54690
Orchiectomy, laparoscopy, surgical
55175
Scrotoplasty; simple
55180
Scrotoplasty; complicated
55899
Unlisted procedure, male genital system
55970
Intersex surgery; male to female [a series of staged procedures that
includes
Male genitalia; removal, penile dissection, urethral transposition,
creation of
Vagina and labia with stent placement]
55980
Intersex surgery; female to male [a series of staged procedures that
include
Penis and
Scrotum formation by graft, and prostheses placement]
56625
Vulvectomy simple; complete
56805
Clitoroplasty for intersex state
57106
Vaginectomy, partial removal of vaginal wall;
57107
w/ removal of paravaginal tissue (radical Vaginectomy)
57110
Vaginectomy, complete removal of vaginal wall;
57111
w/ removal of paravaginal tissue (radical Vaginectomy)
57335
Vaginoplasty for intersex state
58150
Total abdominal hysterectomy, w/ or w/out rmvl of tube(s), w/ or
w/out rmvl of
ovary(s)
58180
Supracervical abdominal hysterectomy, w/ or w/out rmvl of tube(s),
w/ or
w/out rmvl of ovary(s)
58260
Vaginal hysterectomy, for uterus 250
g or less
58262
w/ removal of tube(s) and/or
ovary(s)
58275
Vaginal hysterectomy, w/ total or
partial Vaginectomy;
58280
w/ repair of enterocele
58285
Vaginal hysterectomy, radical
58290
Vaginal hysterectomy, for uterus greater than 250 g;
58291
w/ removal of tube(s) and/or
ovary(s)
58541
Laparoscopy, surgical, Supracervical hysterectomy, for uterus 250 g or
less;
58542
w/ removal of tube(s) and/or ovary(s)
58543
Laparoscopy, surgical, Supracervical hysterectomy, for uterus greater
than
250g;
58544
w/ removal of tube(s) and/or ovary(s)
58550
Laparoscopy, surgical, w/ vaginal
hysterectomy, for uterus 250 g or less;
58552
w/ removal of tube(s) and/or ovary(s)
58553
Laparoscopy, surgical, w/ vaginal hysterectomy, for uterus greater than
250g;
58554
w/ removal of tube(s) and/or
ovary(s)
58570
Laparoscopy, surgical, w/ total hysterectomy, for uterus 250 g or less;
58571
w/ removal of tube(s) and/or ovary(s)
58572
Laparoscopy, surgical, w/ total hysterectomy, for uterus greater than 250
g;
58573
w/ removal of tube(s) and/or
ovary(s)
58661
Laparoscopy, surgical, w/ rmvl of adnexal structures (prtl or ttl
oophorectomy
and/or Salpingectomy
58720
Salpingo-oophorectomy, complete or partial, unilateral or bilateral
58999
Unlisted procedure, female genital system, non-obstetrical (i.e.
metoidioplasty with initial phalloplasty)
J1000
Injection, depo-estradiol cypionate, up to 5 mg
J1071
Injection, testosterone cypionate, 1 mg
J1380
Injection, estradiol valerate, up to 10 mg
J1410
Injection, estrogen conjugated, per 25 mg
J1435
Injection, estrogen, per 1 mg
J3121
Injection, testosterone enanthate, 1
mg
J3145
Injection, testosterone undecanoate, 1 mg